Endocyte Inc. (ECYT): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Endocyte ( ECYT) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 1.3%. By the end of trading, Endocyte fell $0.39 (-1.6%) to $23.42 on average volume. Throughout the day, 1,107,474 shares of Endocyte exchanged hands as compared to its average daily volume of 1,111,800 shares. The stock ranged in price between $23.21-$24.45 after having opened the day at $23.85 as compared to the previous trading day's close of $23.81. Other companies within the Health Care sector that declined today were: Prana Biotechnology ( PRAN), down 17.9%, Medicines Company ( MDCO), down 15.5%, Bio-Path Holdings ( BPTH), down 14.7% and Akers Biosciences ( AKER), down 14.0%.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics. Endocyte has a market cap of $796.4 million and is part of the drugs industry. Shares are up 122.9% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate Endocyte a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Endocyte as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.

On the positive front, Providence Service Corporation ( PRSC), up 34.4%, IsoRay ( ISR), up 19.6%, Amyris ( AMRS), up 19.0% and Intuitive Surgical ( ISRG), up 12.7% , were all gainers within the health care sector with Celgene Corporation ( CELG) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

A Small Biotech Sells for Less Than Cash

A Small Biotech Sells for Less Than Cash

A Small, but Promising Biotech Stock

A Small, but Promising Biotech Stock

4 Biotech Stocks Under $10 to Trade for Breakouts

Why Endocyte (ECYT) Stock Is Declining Today